drugset / Trial / NCT07612150
A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as compared to participants receiving placebo.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2028-04-30
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TML-6 | Small molecule | 100 mg | Oral |
| Subject | TML-6 | Small molecule | 200 mg | Oral |